Fig. 7: Myo1C mutagenesis-association in human cancers and analysis of dysregulated oncogenic pathways in Myo1C-mutated human cancers.

a The mutagenesis rate of Myo1C, p53, and mTOR in different human tissue cancer samples based on the COSMIC database. b The gene expression rate of Myo1C, p53, and mTOR in different human tissue cancer samples based on the COSMIC database. c Heatmap displaying the associations between Myo1C non-synonymous somatic mutations and the enrichment score (ES) of oncogenic pathways across TCGA cancers, combined (Pan-cancer) and stratified per cancer type (Per-cancer). The p values are derived from linear regression models. Pathways with a significant association in the Pan-cancer analysis (FDR < 0.1) are displayed. Beta coefficients above 0 (red) indicate a positive association between the pathway ES and the presence of Myo1C non-synonymous mutations; Beta coefficients below 0 (blue) represent a negative association. The size of the radius represents the negative Log10 p value. The number and proportion of samples harboring Myo1C non-synonymous mutations are represented by Pan-cancer and Per-cancer. Tumor types having less than three samples harboring Myo1C non-synonymous mutations are omitted in the Per-cancer analysis but retained in the Pan-cancer analysis. d Box plots showing the enrichment scores of four representative oncogenic pathways in Myo1C mutated and non-mutated groups in pan-cancer samples. Centerline, box limits, and whiskers represent the median, interquartile range, and 1.5x interquartile range. The p-values are derived from linear regression analyses. An unpaired t-test was used for the statistical analysis. n = 122 for Myo1C mutated samples, n = 9326 for Myo1C non-mutated samples. Source data are provided as a Source Data file.